Key statistics
As of last trade Roche Holding AG (RHO6:FRA) traded at 47.85, -2.36% below its 52-week high of 49.00, set on Feb 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 47.85 |
|---|---|
| High | 47.85 |
| Low | 47.85 |
| Bid | 47.81 |
| Offer | 48.41 |
| Previous close | 48.60 |
| Average volume | 413.78 |
|---|---|
| Shares outstanding | 6.47bn |
| Free float | 341.17m |
| P/E (TTM) | 21.82 |
| Market cap | 371.01bn USD |
| EPS (TTM) | 2.62 USD |
| Annual div (ADY) | 1.28 EUR |
|---|---|
| Annual div yield (ADY) | 2.64% |
| Div ex-date | Mar 28 2025 |
| Div pay-date | May 14 2025 |
Data delayed at least 15 minutes, as of Feb 10 2026 07:10 GMT.
More ▼
- Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
- [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
- FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
- Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu
- Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
- Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
- European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
- Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
More ▼
